Csi-103

N/A

Report date: 2024/09/25 11:14:42
NME

Base Information

Drug NameCsi-103
Drug Alias NameCsi-103Csi103
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionRNA interferenceProprotein convertase subtilisin kexin type 9 inhibitorsApolipoprotein C-III inhibitors
TargetsApolipoprotein C-IIIProprotein convertase subtilisin kexin type 9
Therapy Area/IndicationsHyperlipidemiasHyperoxaluria, PrimaryLiver Cirrhosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCurigin Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCurigin Co Ltd
Inactive CompaniesN/A
Active IndicationsHyperlipidemiasHyperoxaluria, PrimaryLiver Cirrhosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A